Poseida Therapeutics (NASDAQ:PSTX) Posts Earnings Results, Beats Estimates By $0.11 EPS

Poseida Therapeutics (NASDAQ:PSTX) posted its earnings results on Monday. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11, Zacks reports. Poseida Therapeutics had a negative net margin of 131.95% and a negative return on equity of 97.36%. The business had revenue of $25.97 million for the quarter, compared to analyst estimates of $13.75 million.

Poseida Therapeutics Stock Down 1.6 %

PSTX stock traded down $0.05 during midday trading on Wednesday, hitting $3.08. 391,796 shares of the company’s stock were exchanged, compared to its average volume of 607,989. The stock has a market capitalization of $298.64 million, a price-to-earnings ratio of -2.63 and a beta of 0.53. The company has a current ratio of 2.56, a quick ratio of 2.56 and a debt-to-equity ratio of 0.69. The firm has a 50 day moving average price of $3.04 and a 200-day moving average price of $3.07. Poseida Therapeutics has a 12-month low of $1.83 and a 12-month high of $4.27.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Poseida Therapeutics in a report on Tuesday.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.